Ingrid, Jørgen og Nikolai oppsummerer etter beste evne årets ESCMID (en av verdens største infeksjonsmedisinske konferanser) og vårmøtet (kanskje en av verdens minste infeksjonskonferanser) i denne reporasje-baserte episoden av Pestpodden.
Referanser:
1. White NM, et al. Effectiveness of oral care for the prevention of non-ventilator hospital-acquired pneumonia (HAPPEN): a multicentre, stepped-wedge, cluster-randomised trial in Australia. Lancet Infect Dis. 2026.
2. Israelsen SB, et al. Short-course antibiotic therapy of 5 days in community-acquired pneumonia (CAP5): study protocol for a randomised controlled trial. BMJ Open. 2023;13:e069013. doi: 10.1136/bmjopen-2022-069013.
3. Chanderraj R, et al. Mortality of Patients With Sepsis Administered Piperacillin-Tazobactam vs Cefepime. JAMA Intern Med. 2024;184(7):769-77.
4. Azevedo LCP, et al. Using the 2026 Surviving Sepsis Campaign Guidelines in Practice. Crit Care Sci. 2026;38:e20260036.
5. Doumat G, et al. Short Versus Longer Antibiotic Duration for Community-Acquired Pneumonia : A Multicenter Target Trial Emulation. Ann Intern Med. 2026;179(5):629-36.
6. Overdevest AG, et al. Antibiotic treatment for 1 day versus 4–7 days in patients with acute cholangitis after adequate endoscopic biliary drainage (COBRA): study protocol for a randomized controlled trial. Trials. 2026. doi: 10.1186/s13063-026-09524-7. PubMed: PMID 41689066.
7. Turner NA, et al. Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial. JAMA. 2025.
8. Kristensen LH, et al. Diagnostic accuracy of dipsticks for urinary tract infections in acutely hospitalised patients: a prospective population-based observational cohort study. BMJ Evid Based Med. 2025;30(1):36-44.
9. Giamarellos-Bourboulis EJ, et al. Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial. JAMA. 2026;335(9):775-86.
Hosted on Acast. See acast.com/privacy for more information.
